Home > Focus Areas > DLBCL Connect > Post
  • Saved

4yr

Innovative therapies based on molecular orientation in patients with Relapse and Refractory diffuse large B cell lymphoma, results of LNH-EP1 study - PubMed

Innovative therapies based on molecular orientation in patients with Relapse and Refractory diffuse large B cell lymphoma, results of LNH-EP1 study - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/34165816/

doi: 10.1002/ajh.26280. Online ahead of print. 1 DITEP, Gustave Roussy, Villejuif, France. 2 INSERM U1170, Gustave Roussy, Villejuif, France. 3 Translational research hematological laboratory, Gustave Roussy, Villejuif, France. 4 Hematology Department, Gustave Roussy, Villejuif, France. 5 Medical Imaging Department, Gustave Roussy, Villejuif, France. 6 Department of Medical Biology and Pathology, Gustave Roussy, Villejuif, France.

  • 4yr
    It’s surprising in this study that more patients were not eligible for standard treatments and given the broadening options in the past year, it would be important that this study be confirmed in a larger dataset

You might also like